PDCD1 and metastatic melanoma: To evaluate the therapeutic value of the MHC-I signature overexpression, we used clinical and RNA-seq data of patients treated with either pembrolizumab or nivolumab as the anti-PD-1 therapy for their metastatic melanoma (17).